Peter Gwynne | May 9, 1999 | 5 min read
As an issue on the cusp of science and social policy, the value of marijuana in medicine refuses to go away. For several years, researchers wishing to undertake clinical trials of marijuana's medical effects on humans have claimed that the National Institute on Drug Abuse (NIDA), the White House Office of National Drug Control Policy (ONDCP), and the Food and Drug Administration (FDA) are stonewalling by insisting that the protocols are unacceptable. Those organizations complain that several pr